Introduction
Chronic heart failure (CHF) is a major public health problem. Diagnosis of CHF carries substantial risk of morbidity and mortality, despite advances in management [1] . The aims of CHF treatment are to reduce the risk of mortality, control symptoms and improve quality of life [2] . Optimal implementation of evidence-based therapies such as neurohormonal blockade with adequate doses of these drugs can improve patients' outcomes [2] [3] . The rate of use of renin-angiotensin-aldosterone system blockers (ACEinhibitors, angiotensin receptor blockers, aldosterone blockers) and beta-adrenergic blockers is satisfactory. However, the number of patients treated with appropriate doses is suboptimal [4] .
The aim of the present analysis is to describe the characteristics of ambulatory CHF patients treatment in one of Lithuania's university centres. The analysis covers uptitration peculiarities of standard neurohormone blockers.
Material and methods
Patients' data from our centre were entered in the European Society of Cardiology EURObservation Research Programme Heart Failure Long-Term Registry (ESC HFL-TR) on a one-day-per-week basis from May 2011 to March 2013. Follow-up data were registered one year later based on a visit to the clinical centre after 12 months or followup by phone. Registered data includes information about patient's physical examination, previous history, co-morbidities, treatment, laboratory data, and changes in HF treatment after 12 months. Statistical analysis was performed 
Results
Patients' characteristics. CHF cohort was consisted of 240 patients. The age was in an average of 66 yrs (74-56 yrs) and the majority of patients were male. Medium systolic blood pressure (SBP) was 137 mmHg (151 -120 mmHg) and almost 13% of patients who entered the registry had SBP of ≤110 mmHg. The mean heart rate (HR) of the patients was 72 beats per minute (84-65 bpm). The medium left ventricular ejection fraction (LVEF) was 30% (45-20%); only 24% of all patients had LVEF >45%. Atrial fibrillation was registered for 6% of patients. Just for a small proportion of CHF patients was known diabetes mellitus (12,5%). Patients' characteristics data are presented on Table 1 .
Up-titration of neurohormone blockers. In our centre 67,1% of patients received ACE inhibitors at target doses ( Figure 1 ). However, 41,7% of patients were still in up-titration phases, one third (34,3%) had not reached target doses due to symptomatic hypotension, 4,6% -due to worsening renal function and just a few patients had not reached target doses due to cough (1,9%) or hyperkalemia (0,9%).
Beta blockers (BBs) were up-titrated to target doses for 82,5% of patients. The main reasons for failure to reach the target dose of BBs were as follows: symptomatic bradycardia (12,7%) and symptomatic hypotension (10,7%). Other reasons were as follows: bronchospasm -5,4% of patients, worsening HF -6,3% of patients and for the rest 11,2% of patients the reasons were "other or unknown". Mineralocorticoid receptor antagonists (MRAs) were up-titrated to a target doses just for half of the patients -52,1%. The most frequent reason for not reaching target doses was hyperkalemia (15,4%) and just a few patients were not up-titrated because of worsening renal function (2,2%) or gynecomastia (2,2%). It is noticeable that for almost 19,1% of cases the reasons of absence of up-titration were not provided ("other or unknown").
Analyzing dose titration peculiarities of angiotensin II receptor blockers (ARBs), only 16,7% of patients in our centre received ARBs at target doses.
Discussion
Guidelines of the management of CHF recommend a long-term treatment with three main neurohormonal blockers: ACE inhibitors, BBs, and MRAs [5, 6] . Optimal therapy for CHF involves target-dose titration of medications [6] . According to European Society of Cardiology guidelines, neurohormonal blockers should be started with a very low initial dose and then up-titrated to the maximal tolerated dose [7] . Analyzing the number of patients receiving optimal background drug therapy, 67,1% of patients in our centre received ACE inhibitors at target dose, while data from other ESC HF Long-Term Registry centres show that the target dose have been reached just for 29,3% of patients Prior hospitalization, % 10
Ischaemic aetiology, % 10,71
Atrial fibrillation, % 6,25
Diabetes mellitus, % 12,5
Hypertension, % 75,83 Chronic obstructive pulmonary disease, % 10 Prior stroke/ transient ischemic attack, % 12,08
Hepatic dysfunction, % 4,58 
Conclusions
1. ACE-inhibitors, beta-blockers and mineralocorticoid receptors antagonists, except angiotensin receptors blockers, were prescribed in a guideline-recommended target doses.
2. The main reasons why the target doses of neurohormone blockers have not been achieved were as follows: symptomatic hypotension for ACE-inhibitors, symptomatic bradycardia for beta-blockers and hyperkalemia for mineralocorticoid receptors antagonists.
